July 20, 2022
IPGaia, Inc.
Tokyo Medical and Dental University
IPGaia, Inc. and Tokyo Medical and Dental University
Announce Master Collaborative Research and Development Agreement
IPGaia, Inc., ("IPG") and Tokyo Medical and Dental University ("TMDU"), based inTokyo, Japan, have entered into a Master Collaborative Research and Development
Agreement ("this agreement") dated July 6th, 2022. This agreement establishes a formal
framework for the incorporation of promising drug target leads from TMDU into IPG’s drug
discovery platform.
The program enables TMDU to propose drug targets to IPG for identification anddevelopment of lead compounds or modalities with the goal of licensing clinical development
candidates to pharmaceutical companies. IPG is soliciting drug target leads from a wide rangeof research institutions, including global academia and pharmaceutical companies, and issteadily expanding to the third institution, TMDU, to receive drug target leads from academia,
both domestically and internationally.
For patients, personalized medicine holds great promise for the effective treatment andprevention of disease. For the pharmaceutical industry, personalized medicine provides theopportunity to achieve substantial clinical advances by tailoring treatments to the genes andpersonal circumstances that make every patient different.
“To create breakthrough healthcare innovation, TMDU is striving for enhancement ofacademic-industrial partnerships by leveraging TMDU’s high quality education, research orclinical assets.” Dr. Arinobu Tojo, Executive Vice President of TMDU states. “We hope thecollaboration with IPG will further accelerate social implementation of TMDU’s innovative
medical needs.”“It is our great pleasure and honor to have this agreement with TMDU which is one of theleading medical universities in Japan.” Yasu Yamaguchi, Ph.D., President and CEO of IPG
states. “This enables IPG to access to promising drug discovery seeds and to create highly
innovative medicines. In this sense, IPG moves forward to contributing to solving the global
social issues such as high healthcare costs and to extending the healthy life expectancy.”

[About IPG]
IPG was established on October 26, 2021, as a wholly owned subsidiary of the Healthcare
New Platform Fund where Whiz. Partners Inc. (Headquarters: Minato-ku, Tokyo; President
and CEO: Atsushi Matsumura) has been the general partner. IPG will generate compositionof matter patents for new chemical entities by conducting non-clinical research anddevelopment activities and make variety of transactions mainly with pharmaceuticalcompanies. IPG has already concluded a comprehensive partnership agreement with Axcelead,Inc.

andAxcelead

Drug

Discovery

Partners,

Inc.

(http://ip-g.co.jp/wp-content/uploads/2022/01/0c91379ab46f05f47d691359e8e8c721.pdf) . By collaborating
among the parties to build a next stage drug discovery platform, it would be possible togenerate high quality innovative pharmaceuticals in a shorter period of time and lower cost.
As for the pharmaceutical industry, the trend of the horizontal division of labor businessmodel would be more accelerating. IPG plays a role as a platformer for creating pre-clinicalstage innovative new medicines.
【About TMDU】
Tokyo Medical and Dental University was established as a national educational institution
for dentistry on October 12, 1928, and currently located in the Yushima/Shoheizaka area ofTokyo, which is considered sacred ground for scholarship and learning in Japan. Since then,as Japan’s only comprehensive medical university and graduate school, TMDU has provided
advanced medical treatment through a fusion of the medical and dental fields and worked tocultivate “ professionals with knowledge and humanity,” thereby contributing to humanhealth and the well-being of society.
Contacts;
IPGaia, Inc.
Eri Yokota; PR Manager
Address：36F Atago Green Hills Mori Tower, 2-5-1 Atago, Minatoku, Tokyo Japan
Mobile：070-2485-4358
E-mail: contact@ip-g.com
TMDU Public Relations Office, General Coordination and Secretarial Section
TEL: +81-(0) 3-5803-5833
E-mail: kouhou.adm@tmd.ac.jp